Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05150444
Other study ID # Z3-3212
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2, 2022
Est. completion date June 30, 2023

Study information

Verified date February 2024
Source University Medical Centre Ljubljana
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the effect of cognitive training combined with physical exercise on cognitive function, physical performance and frailty indicators in the hemodialysis population.


Description:

The prevalence of cognitive impairment in hemodialysis (HD) patients is extremely high. Despite the well-documented benefits of interventions on cognitive function, there is a widespread call for effective strategies that will show the long-term consequences in patients undergoing dialysis. A randomized controlled intervention trial to examine the effects of a combined non-pharmacological intervention in the form of intradialytic physical exercise and intradialytic cognitive training on cognitive function, indicators of frailty, and physical performance measures in HD patients will be conducted. The group of patients receiving the study intervention will be compared to the control group receiving standard HD care. The duration of the intervention will be 12 weeks (3 days a week). We will use sensitive instruments (cognitive domain tests) to assess cognitive functions. The primary outcome of the study at 12 weeks will be performance on the Alertness subtest of the computerized Test of Attentional Performance. Secondary study outcomes will be: Performance in other domains of cognitive function (executive function, psychomotor speed, information processing efficiency, working memory, attention), physical fitness (10 repetition sit-to-stand test, timed up and go test, handgrip strength test, spontaneous gait speed, Stork balance test), and assessment of frailty (Edmonton Frail Scale). Study outcomes will be assessed at baseline and immediately after the 12-week intervention. This study will be among the first to test the synergistic effects of a uniquely designed physical exercise and cognitive training intervention on functional status in HD patients.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date June 30, 2023
Est. primary completion date January 25, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - dialysis patients on renal replacement therapy with chronic hemodialysis - duration of hemodialysis treatment for at least 3 months - capable of independent walking and independent feeding Exclusion Criteria: - the presence of chronic malignant or infectious disease - uncontrolled arterial hypertension with an average of the last five pre-dialysis blood pressure values above 180/100 mm Hg, - unstable angina pectoris or Canadian Cardiovascular Society class 2-4, - heart failure New York Heart Association class 3 and 4, - the presence of a psychotic illness or a mental disability, - a condition with an amputated limb (more than 2 fingers on the lower limb and / or more than 2 fingers on the upper limb) - any other condition that causes the clinical unstability of the patient (i.e. repetitive gastrointestinal hemorrhagies, liver cirrhosis with frequent exacerbations)

Study Design


Intervention

Other:
Cognitive and physical exercise training
12 weeks (3 times a week): patients will cycle on an adapted ergometer during their dialysis procedure. The exercise program will be run by kinesiologists. Participants will start with 15 minutes of cycling and then gradually increase the time and intensity. After the physical exercise session, they will continue with cognitive training. This training will be done on a tablet computer on a CogniFit platform (~30 minutes). The "brain games" on mentioned platform automatically adapt to individual cognitive abilities.

Locations

Country Name City State
Slovenia University Medical Centre Ljubljana Osrednjeslovenska

Sponsors (1)

Lead Sponsor Collaborator
University Medical Centre Ljubljana

Country where clinical trial is conducted

Slovenia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Test of Attentional Performance (TAP) score The Test of Attentional Performance (TAP) is a software package that can be used primarily to examine attention functions. The rationale for the selection of the main outcome: low learning effect, most probably affected by physical exercise, attention is one of the most affected cognitive domains in dialysis patients. From the TAP test battery, subtests Alertness, Selective attention, and Divided attention will be included. baseline, after 12 weeks
Secondary Change in Montreal Cognitive Assessment (MoCA) score Montreal Cognitive Assessment (MoCA) is a global cognitive function assessment tool covering eight cognitive domains and is used to screen patients for cognitive impairment. baseline, after 12 weeks
Secondary Change in Trail Making Test A and B score The psychomotor speed and executive function will be measured by Trail Making Test A and B. baseline, after 12 weeks
Secondary Change in Symbol Digit Modalities Test (SDMT) score Symbol Digit Modalities Test (SDMT) will be used to assess the psychomotor speed, efficiency of information processing, ability to switch between mental sets of the information and to maintain and manipulate information in working memory. It is a reliable and valid test for assessing information processing speed and efficiency and executive functioning domains. baseline, after 12 weeks
Secondary Change in 10 repetition sit-to-stand test time Performance of the sit-to-stand test involves activation of the lower limb muscles; the test measures lower limb strength. Participants are required to 10 times stand up from and sit down on an armless chair as quickly as possible. Their arms should be folded across their chest. baseline, after 12 weeks
Secondary Change in Stork balance test time Stork balance test time as a measure of balance. baseline, after 12 weeks
Secondary Change in frailty score Frailty indicator will be assessed by the Edmonton Frail Scale (EFS). The EFS score ranges from zero to 17 points. Severe Frailty is defined as a score of 12-17 possible points; apparent vulnerability is a score of 6-11 points; and non-frail is a score of 5 or less points. baseline, after 12 weeks
Secondary Change in timed-up-and go (TUG) test time The Timed Up and Go (TUG) test is a simple evaluative test used to measure functional mobility. It will be used to estimate risk of falling and ability to maintain balance while walking and while walking and talking (TUG-dual). baseline, after 12 weeks
Secondary Change in handgrip strength (HGS) test Handgrip strength test as a measure of upper body strength (in kilograms). baseline, after 12 weeks
Secondary Change in Kidney Disease Quality of Life Short Form (KDQoL-SF) score Kidney Disease Quality of Life Short Form (KDQOL-SF) as a measure of quality of life. The scoring procedure first transforms the raw precoded numeric values of items to a 0-100 possible range, with higher transformed scores always reflecting better quality of life. Scores are evaluated according to summary scores: a mental component summary (MCS) and a physical component summary (PCS). baseline, after 12 weeks
Secondary Change in spontaneous gait speed Spontaneous gait speed test (4 meters) as a measure of functional mobility (in m/s). baseline, after 12 weeks
Secondary Change in Brain-derived neurotrophic factor (BDNF) concentration BDNF is a neurotrophic protein that promotes neurons' survival and differentiation. baseline, after 12 weeks
Secondary Change in Interleukin-6 concentration Interleukin-6 serum concentration baseline, after 12 weeks
Secondary Change in C-reactive protein (CRP) concentration C-reactive protein serum concentration baseline, after 12 weeks
Secondary Change in hemoglobin concentration Hemoglobin blood concentration baseline, after 12 weeks
Secondary Change in urea concentration Urea serum concentration baseline, after 12 weeks
Secondary Change in phosphate concentration Phosphate serum concentration baseline, after 12 weeks
Secondary Change in albumin concentration Albumin serum concentration baseline, after 12 weeks
Secondary Change in fat tissue index Fat tissue index measured by bioimpedance analysis (BCM Fresenius Medical Care) baseline, after 12 weeks
Secondary Change in lean tissue index Lean tissue index measured by bioimpedance analysis (BCM Fresenius Medical Care) baseline, after 12 weeks
Secondary Change in mental fatigue Mental fatigue measured by Visual Analogue Scale (M-VAS) ranged 0-100, where higher score indicates higher mental fatigue. baseline, after 12 weeks
Secondary Change in hematocrit concentration Hematocrit blood concentration baseline, after 12 weeks
Secondary Change in creatinine concentration Creatinine serum concentration baseline, after 12 weeks
Secondary Change in sodium concentration Sodium serum concentration baseline, after 12 weeks
Secondary Change in potassium concentration Potassium serum concentration baseline, after 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06386172 - Electronic Decision-support System to Improve Detection and Care of Patients With Chronic Kidney Disease in Stockholm N/A
Recruiting NCT04910867 - APOL1 Genetic Testing Program for Living Donors N/A
Completed NCT03434145 - Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases N/A
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Terminated NCT05022329 - COVID-19 Vaccine Boosters in Patients With CKD Phase 2/Phase 3
Not yet recruiting NCT04925661 - HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia Phase 1
Recruiting NCT04961164 - Resistant Starch Prebiotic Effects in Chronic Kidney Disease N/A
Completed NCT05015647 - Low Protein Diet in CKD Patients at Risk of Malnutrition N/A
Completed NCT03426787 - Helping Empower Liver and Kidney Patients N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Completed NCT04363554 - The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease N/A
Recruiting NCT04831021 - Pre- or Per-dialytic Physical Exercise : a Cardioprotective Role? N/A
Terminated NCT04877847 - Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury N/A
Recruiting NCT04422652 - Combination of Novel Therapies for CKD Comorbid Depression Phase 2
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Not yet recruiting NCT06330480 - Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease N/A
Recruiting NCT03176862 - Left Ventricular Fibrosis in Chronic Kidney Disease N/A
Terminated NCT02539680 - Intestinal Phosphate Transporter Expression in CKD Patients N/A